Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.2-0.6 ug/mL.
1 Primary · 1 Secondary · Reporting Duration: 100 days
60 Total Participants · 1 Treatment Group
Primary Treatment: Alemtuzumab · No Placebo Group · Phase 2
Age 6 - 30 · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: